Translational Medicine
Open Access
ISSN: 2161-1025
+44 1223 790975
ISSN: 2161-1025
+44 1223 790975
Zhengyuan Xia
University of Hong Kong, China
Scientific Tracks Abstracts: Transl Med
Brief ischemia and reperfusion to no vital organs, referred to as remote ischemic preconditioning (RIPC), can help the heart to withstand a prolonged ischemia during cardiac surgeries in non-diabetic patients. However, RIPC cardio-protection is reduced/ diminished in diabetic patients with increased oxidative stress. Notably, recent large-scale clinical trials showed that RIPC, when induced immediately before surgery in patients anesthetized solely or primarily with propofol, an anesthetic reported to attenuate RIPC cardio-protection, is potentially detrimental evidenced as more than doubled or about 50% more patient death in the RIPC than in the sham-RIPC group, which is of clinical significance although the trials were not powered to detect statistically between-group differences. By contrast, RIPC applied before/during hospital admission increased myocardial salvage-index (area at risk-final infarct size)/area at risk) without increasing patient death. Experimentally, we demonstrated that repeated RIPC for three consecutively days reduced myocardial infarction in diabetic rats by activating mitochondrial STAT3, a key molecule in RIPC cardio-protection. RIPC at a remote time may allow the second-window cardio-protection to help better withstand ischemia during cardiac surgery and merits clinical trials to confirm.
Zhengyuan Xia is an Associate Professor in Department of Anesthesiology at University of Hong Kong, China. He completed his PhD in Pharmacology & Therapeutics at University of British Columbia, Canada in 2004; MB (Medical Doctoral program) and Master of Medicine from China. He has published more than 120 research papers in internationally reputed journals, and serve as peer Reviewer of reputed journals like The Lancet, Diabetes and Anesthesiology.
Email: zhengyuan_xia@yahoo.com